Prestige Consumer Healthcare (PBH) Stock Overview
Develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
PBH Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Prestige Consumer Healthcare Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$48.29 |
| 52 Week High | US$79.09 |
| 52 Week Low | US$42.62 |
| Beta | 0.35 |
| 1 Month Change | 1.19% |
| 3 Month Change | -14.92% |
| 1 Year Change | -38.76% |
| 3 Year Change | -17.86% |
| 5 Year Change | -6.88% |
| Change since IPO | 172.06% |
Recent News & Updates
Narrative Update • Jul 02
PBH: Future Upside Will Rely On Successful OTC Wellness Integration
Analysts have revised their price target for Prestige Consumer Healthcare from $81.00 to $75.00, citing updated assumptions regarding revenue growth, profit margins, and a lower projected future P/E multiple. What’s in the News for Prestige Consumer Healthcare Prestige Consumer Healthcare completed a US$1.045b cash acquisition of the OTC Wellness Business, including the Breathe Right brand, financed primarily with a term loan and cash on hand, according to the amended material event report.
Narrative Update • Jun 18
PBH: Future Brand Acquisitions And Buybacks Will Drive Upside Potential
Analysts maintained their $66.80 price target for Prestige Consumer Healthcare, citing stable assumptions for fair value, discount rate, revenue growth, profit margin and future P/E in their latest update. What’s in the News for Prestige Consumer Healthcare Prestige Consumer Healthcare reported fourth quarter fiscal 2026 adjusted EPS of $1.23, missing estimates, with revenue showing a year over year decline and fiscal 2027 revenue guidance of $1.10b to $1.12b and adjusted diluted EPS guidance of $4.42 to $4.51 coming in slightly below analyst consensus, according to recent earnings coverage.Recent updates
Narrative Update • Jul 02
PBH: Future Upside Will Rely On Successful OTC Wellness Integration
Analysts have revised their price target for Prestige Consumer Healthcare from $81.00 to $75.00, citing updated assumptions regarding revenue growth, profit margins, and a lower projected future P/E multiple. What’s in the News for Prestige Consumer Healthcare Prestige Consumer Healthcare completed a US$1.045b cash acquisition of the OTC Wellness Business, including the Breathe Right brand, financed primarily with a term loan and cash on hand, according to the amended material event report.Narrative Update • Jun 18
PBH: Future Brand Acquisitions And Buybacks Will Drive Upside Potential
Analysts maintained their $66.80 price target for Prestige Consumer Healthcare, citing stable assumptions for fair value, discount rate, revenue growth, profit margin and future P/E in their latest update. What’s in the News for Prestige Consumer Healthcare Prestige Consumer Healthcare reported fourth quarter fiscal 2026 adjusted EPS of $1.23, missing estimates, with revenue showing a year over year decline and fiscal 2027 revenue guidance of $1.10b to $1.12b and adjusted diluted EPS guidance of $4.42 to $4.51 coming in slightly below analyst consensus, according to recent earnings coverage.Analysis Article • Jun 16
Prestige Consumer Healthcare (PBH) Stock Could Be 30.1% Undervalued After Weak Earnings And Guidance
Prestige Consumer Healthcare (PBH) is back in focus after fiscal 2026 earnings missed estimates, revenue declined year over year, and guidance for fiscal 2027 came in below consensus expectations. See our latest analysis for Prestige Consumer Healthcare. Those weaker fiscal 2026 results, cautious fiscal 2027 guidance, and the new investor investigation have coincided with a sharp loss of momentum, with Prestige Consumer Healthcare’s share price down 25.1% over 90 days and its 1 year total...Narrative Update • Jun 04
PBH: Future M&A And Share Repurchases Will Support Upside Potential
Analysts have reset their price target for Prestige Consumer Healthcare from $78.50 to $66.80, reflecting updated views on discount rates, revenue growth assumptions, profit margins, and a lower future P/E of 12.55 versus the prior 16.20. What's in the News Prestige Consumer Healthcare is the subject of multiple securities fraud investigations following a fiscal 2026 Q4 earnings miss and an 11.35% share price drop, with law firms including Schall Law Firm, Levi & Korsinsky, and the Law Offices of Howard G.
New Narrative • Jun 01
OTC Health Demand And Eye Care Supply Efforts Will Support Steady Future Performance
Catalysts About Prestige Consumer Healthcare Prestige Consumer Healthcare sells over the counter consumer health products across categories such as eye care, gastrointestinal relief, women's health and therapeutic skin care. What are the underlying business or industry changes driving this perspective?Seeking Alpha • May 17
Prestige Consumer Healthcare: Better Valuation, But Too Much Uncertainty To Buy
Summary Prestige ended its Fiscal Year 2026 with a big earnings miss. It appears the company will have a fairly slow start to FY'27 as well. Acquisitions should add significantly to the top line, but they will add more debt to an already leveraged balance sheet. Prestige's valuation has gotten more attractive in recent months, but there are too many questions for me to get bullish just yet. Read the full article on Seeking AlphaNew Narrative • May 17
Eye Care Capacity Investments And E Commerce Expansion Will Support Long Term Consumer Health Strength
Catalysts About Prestige Consumer Healthcare Prestige Consumer Healthcare markets and acquires over the counter consumer health brands across eye care, gastrointestinal, oral care, women's health and therapeutic skin care categories. What are the underlying business or industry changes driving this perspective?Narrative Update • May 04
PBH: Disciplined M&A And Share Repurchases Will Drive Future Upside Potential
Analysts kept their $78.50 price target on Prestige Consumer Healthcare unchanged, citing steady assumptions for fair value, discount rate, revenue growth, profit margin and future P/E. Together, these factors support a consistent outlook on the stock's valuation framework.Narrative Update • Apr 18
PBH: Brand Investment And Share Repurchases Will Support Future Upside Potential
Analysts kept their price target for Prestige Consumer Healthcare steady at $78.50, citing unchanged assumptions around fair value, discount rate, revenue growth, profit margin and future P/E that together point to a consistent view of the company’s long term potential. What's in the News Completed a share repurchase program totaling 3,064,806 shares, representing 6.24% of shares, for US$207 million under the buyback announced on May 14, 2024 (Key Developments).Narrative Update • Apr 04
PBH: Buybacks And Brand Investment Will Support Future Capital Deployment Opportunities
Analysts have adjusted the price target for Prestige Consumer Healthcare to $78.50 from $77.83, reflecting updated views on revenue growth assumptions, profit margins, and the future P/E multiple. What's in the News Completed repurchase of 3,064,806 shares, representing 6.24% of shares, for a total of $207m under the buyback program announced on May 14, 2024, including 766,559 shares, or 1.59%, bought between October 1, 2025 and December 31, 2025 for $45.82m (Key Developments).Narrative Update • Mar 21
PBH: Buybacks And Brand Investment Will Drive Future Shareholder Value
Analysts kept their $77.83 price target for Prestige Consumer Healthcare unchanged, citing stable fair value, discount rate, revenue growth, profit margin, and future P/E assumptions in their latest update. What's in the News Completed share repurchase of 3,064,806 shares, or 6.24% of outstanding stock, for a total of US$207 million under the buyback program announced on May 14, 2024.Narrative Update • Mar 06
PBH: Buybacks And Brand Investment Will Support Long Term Value Creation
Analysts kept their price target for Prestige Consumer Healthcare steady at $77.83, reflecting unchanged views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Completed share repurchase of 3,064,806 shares, or 6.24% of outstanding stock, for a total of $207 million under the buyback program announced on May 14, 2024.Narrative Update • Feb 19
PBH: Buybacks And Brand Investments Will Drive Long Term Value Creation
Analysts have nudged their price target on Prestige Consumer Healthcare higher to about $77.83 from roughly $77.33, citing updated assumptions around revenue growth, profit margins, the discount rate, and a slightly lower future P/E multiple. What's in the News Completed share repurchase of 3,064,806 shares, representing 6.24% of shares, for a total of US$207 million under the buyback announced on May 14, 2024.Narrative Update • Feb 04
PBH: Buybacks And M&A Firepower Will Support Long Term Value Creation
Analysts have nudged their price target on Prestige Consumer Healthcare slightly lower, trimming fair value from about $78.00 to roughly $77.33 as they factor in updated assumptions around revenue growth, profit margins and future P/E levels. What's in the News TheraTears, a Prestige Consumer Healthcare brand, plans to launch Eyelid Cleansing Wipes nationwide in February 2026.Narrative Update • Jan 21
PBH: Buybacks And Cash Flow Will Support Long Term Value Creation
Analysts have kept their price target for Prestige Consumer Healthcare steady at US$78.00, reflecting largely unchanged assumptions around discount rate, revenue growth, profit margins, and future P/E expectations. What's in the News TheraTears plans to launch Eyelid Cleansing Wipes and Dry & Tired Preservative Free Lubricant Eye Drops nationwide in February 2026, aimed at consumers dealing with screen-related eye fatigue and dry eye discomfort (Product-Related Announcements).Analysis Article • Jan 09
We Think Prestige Consumer Healthcare (NYSE:PBH) Can Stay On Top Of Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Narrative Update • Jan 06
PBH: Buybacks And M&A Capacity Will Support Long Term Value Creation
Analysts have maintained their fair value estimate for Prestige Consumer Healthcare at $78. Only very small model adjustments to the discount rate, revenue growth, profit margin and future P/E support an unchanged price target.Narrative Update • Dec 20
PBH: Buybacks Will Support Future Cash Deployment Into Accretive M&A
Analysts have modestly reaffirmed their outlook on Prestige Consumer Healthcare, maintaining a price target of 78 dollars per share. They continue to see stable revenue growth, resilient profit margins, and a supportive long term earnings multiple underpinning valuation.Narrative Update • Dec 06
PBH: Buybacks And Cash Flow Will Drive Future M&A Upside
Analysts have modestly raised their price target on Prestige Consumer Healthcare to 78 dollars from 78 dollars, reflecting largely unchanged views on fair value as stable discount rates, revenue growth expectations, profit margins, and future earnings multiples remain intact. What's in the News Completed a share repurchase program totaling 2,298,247 shares (4.65% of outstanding shares) for approximately 161.18 million dollars under the buyback announced on May 14, 2024 (Key Developments) Repurchased 1,150,129 shares (2.34% of outstanding shares) for 75 million dollars between July 1, 2025 and September 30, 2025 as part of the same buyback authorization (Key Developments) Reaffirmed Fiscal 2026 revenue guidance of 1.1 billion to 1.115 billion dollars, with an expected organic revenue decline of approximately 1.5% to 3.0% (Key Developments) Signaled active interest in mergers and acquisitions, citing historically low leverage and more than 1 billion dollars of expected cash flow over the next four years to deploy into disciplined, value accretive deals (Key Developments) Valuation Changes Fair Value Estimate remains unchanged at 78 dollars per share, indicating no material reassessment of intrinsic value.Narrative Update • Nov 22
PBH: Share Repurchases And Cash Flow Will Drive M&A Acceleration
Analysts have revised their price target for Prestige Consumer Healthcare downward to $78.00 from $80.17. This reflects adjusted expectations based on updated growth and valuation metrics.Narrative Update • Nov 05
PBH: Share Buyback And Cash Flow Will Drive Future Upside
Analysts have lowered their price target for Prestige Consumer Healthcare slightly, from $80.80 to $80.17. They cite a modest reduction in projected revenue growth, even though profitability metrics remain stable.Narrative Update • Oct 21
Analysts Trim Prestige Consumer Healthcare Price Target Amid Guidance Cut and Buyback Activity
Analysts have slightly reduced their price target for Prestige Consumer Healthcare from $82.80 to $80.80. This change is due to marginal adjustments to projected valuation metrics and profit assumptions.Narrative Update • Aug 11
Pillar5 Acquisition And Ecommerce Momentum Will Foster Enduring Supply Reliability
The consensus Analyst Price Target for Prestige Consumer Healthcare was lowered to $82.80, primarily reflecting reduced revenue growth expectations and a slight contraction in net profit margin. What's in the News Prestige Consumer Healthcare is actively seeking M&A opportunities, leveraging strong free cash flow and reduced leverage.Analysis Article • Aug 04
Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Price Is Out Of Tune With Earnings
It's not a stretch to say that Prestige Consumer Healthcare Inc.'s ( NYSE:PBH ) price-to-earnings (or "P/E") ratio of...Analysis Article • Jul 17
Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Could Be 47% Below Their Intrinsic Value Estimate
Key Insights Prestige Consumer Healthcare's estimated fair value is US$142 based on 2 Stage Free Cash Flow to Equity...Analysis Article • May 09
These 4 Measures Indicate That Prestige Consumer Healthcare (NYSE:PBH) Is Using Debt Reasonably Well
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Apr 16
Prestige Consumer Healthcare Inc. (NYSE:PBH) Investors Are Less Pessimistic Than Expected
With a median price-to-sales (or "P/S") ratio of close to 3.5x in the Pharmaceuticals industry in the United States...Analysis Article • Mar 05
Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Intrinsic Value Is Potentially 70% Above Its Share Price
Key Insights The projected fair value for Prestige Consumer Healthcare is US$143 based on 2 Stage Free Cash Flow to...Analysis Article • Feb 09
Results: Prestige Consumer Healthcare Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
It's been a pretty great week for Prestige Consumer Healthcare Inc. ( NYSE:PBH ) shareholders, with its shares surging...Analysis Article • Feb 07
Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Jan 16
Pinning Down Prestige Consumer Healthcare Inc.'s (NYSE:PBH) P/S Is Difficult Right Now
It's not a stretch to say that Prestige Consumer Healthcare Inc.'s ( NYSE:PBH ) price-to-sales (or "P/S") ratio of 3.4x...Analysis Article • Dec 04
Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Could Be 45% Below Their Intrinsic Value Estimate
Key Insights Prestige Consumer Healthcare's estimated fair value is US$154 based on 2 Stage Free Cash Flow to Equity...Analysis Article • Nov 03
We Think Prestige Consumer Healthcare (NYSE:PBH) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Sep 10
Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Popularity With Investors Is Under Threat From Overpricing
With a median price-to-sales (or "P/S") ratio of close to 3x in the Pharmaceuticals industry in the United States, you...
New Narrative • Sep 03
Brand Building And Innovations Propel Long-Term Growth Amid Supply Chain Challenges
Investments in brand building and marketing for key products like Hydralyte and Summer's Eve are enhancing consumer awareness and driving revenue growth.Analysis Article • Jul 16
Prestige Consumer Healthcare (NYSE:PBH) Seems To Use Debt Quite Sensibly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • May 22
Revenues Not Telling The Story For Prestige Consumer Healthcare Inc. (NYSE:PBH)
It's not a stretch to say that Prestige Consumer Healthcare Inc.'s ( NYSE:PBH ) price-to-sales (or "P/S") ratio of 2.9x...Analysis Article • Mar 26
Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analysis Article • Mar 05
An Intrinsic Calculation For Prestige Consumer Healthcare Inc. (NYSE:PBH) Suggests It's 50% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Prestige Consumer Healthcare fair value estimate is US$143...Analysis Article • Feb 11
Prestige Consumer Healthcare Inc. (NYSE:PBH) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Shareholders of Prestige Consumer Healthcare Inc. ( NYSE:PBH ) will be pleased this week, given that the stock price is...Shareholder Returns
| PBH | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.3% | 3.0% | -0.7% |
| 1Y | -38.8% | 50.6% | 20.3% |
Return vs Industry: PBH underperformed the US Pharmaceuticals industry which returned 50.6% over the past year.
Return vs Market: PBH underperformed the US Market which returned 20.3% over the past year.
Price Volatility
| PBH volatility | |
|---|---|
| PBH Average Weekly Movement | 5.6% |
| Pharmaceuticals Industry Average Movement | 9.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: PBH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PBH's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 890 | Ron Lombardi | www.prestigebrands.com |
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name.
Prestige Consumer Healthcare Inc. Fundamentals Summary
| PBH fundamental statistics | |
|---|---|
| Market cap | US$2.39b |
| Earnings (TTM) | US$190.30m |
| Revenue (TTM) | US$1.09b |
12.0x
P/E Ratio2.1x
P/S RatioIs PBH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PBH income statement (TTM) | |
|---|---|
| Revenue | US$1.09b |
| Cost of Revenue | US$482.79m |
| Gross Profit | US$605.91m |
| Other Expenses | US$415.61m |
| Earnings | US$190.30m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 06, 2026
| Earnings per share (EPS) | 4.02 |
| Gross Margin | 55.65% |
| Net Profit Margin | 17.48% |
| Debt/Equity Ratio | 52.8% |
How did PBH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/08 22:21 |
| End of Day Share Price | 2026/07/08 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Prestige Consumer Healthcare Inc. is covered by 16 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Olivia Tong Cheang | BofA Global Research |
| John San Marco | Brean Capital Historical (Janney Montgomery) |
| Linda Bolton-Weiser | B. Riley Securities, Inc. |